Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia
暂无分享,去创建一个
R. Vierkant | V. Pankratz | L. Hartmann | A. Degnim | D. Visscher | C. Reynolds | S. Anderson | M. Frost | M. Santisteban | E. B. Barr Fritcher | E. G. Barr Fritcher
[1] N. Saquib,et al. Time-varying effects of prognostic factors associated with disease-free survival in breast cancer. , 2009, American journal of epidemiology.
[2] Sean Davis,et al. Molecular Grading of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.
[3] Mitch Dowsett,et al. Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer , 2008, Clinical Cancer Research.
[4] R. Vierkant,et al. Assessment of the accuracy of the Gail model in women with atypical hyperplasia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Luini,et al. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity , 2008, British Journal of Cancer.
[6] R. Vierkant,et al. Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. , 2008, Journal of the National Cancer Institute.
[7] R. Vierkant,et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Kai Zhang,et al. Utility of SKP2 and MIB-1 in grading follicular lymphoma using quantitative imaging analysis. , 2007, Human pathology.
[9] Mikael Lundin,et al. Generalisability of survival estimates for patients with breast cancer--a comparison across two population-based series. , 2006, European journal of cancer.
[10] Romayne A. Thompson,et al. Age-related lobular involution and risk of breast cancer. , 2006, Journal of the National Cancer Institute.
[11] M. Ellis,et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Cazzaniga,et al. Atypia and Ki-67 Expression from Ductal Lavage in Women at Different Risk for Breast Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.
[13] P. Thomas,et al. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in‐situ hybridization in the evaluation of HER‐2/neu expression in primary breast carcinoma , 2006, Histopathology.
[14] P. Tartter,et al. Immunohistochemical staining for cyclin D1 and Ki-67 aids in the stratification of atypical ductal hyperplasia diagnosed on breast core biopsy. , 2005, American journal of clinical pathology.
[15] C Sotiriou,et al. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] Mitch Dowsett,et al. Proliferation marker Ki-67 in early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] V Shane Pankratz,et al. Benign breast disease and the risk of breast cancer. , 2005, The New England journal of medicine.
[18] R. Mansel,et al. Benign breast disorders. , 2005, The New England journal of medicine.
[19] C. Zalles,et al. Ki-67 Expression in Benign Breast Ductal Cells Obtained by Random Periareolar Fine Needle Aspiration , 2005, Cancer Epidemiology Biomarkers & Prevention.
[20] L. Ford,et al. Prevention of hormone-related cancers: breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] H. Adami,et al. Prognostic implication of estrogen receptor content in breast cancer , 2005, Breast Cancer Research and Treatment.
[22] K. Bloom,et al. Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. , 2004, American journal of clinical pathology.
[23] K. Hess,et al. Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse , 2003, Breast Cancer Research and Treatment.
[24] L. Hartmann,et al. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. , 2003, The New England journal of medicine.
[25] J. Sloane,et al. Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. , 2002, The American journal of pathology.
[26] A. Thor,et al. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] J. Sloane,et al. Immunodetectable cyclin D 1 is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions , 2001, British Journal of Cancer.
[28] S. Fuqua,et al. Histological and biological evolution of human premalignant breast disease. , 2001, Endocrine-related cancer.
[29] R. Chlebowski. Reducing the risk of breast cancer. , 2000, The New England journal of medicine.
[30] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[31] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[32] S. Haga,et al. Prognostic significance of MIB1-determined proliferative activities in intraductal components and invasive foci associated with invasive ductal breast carcinoma , 1999, British Journal of Cancer.
[33] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[34] M. Gnant,et al. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. , 1997, European journal of cancer.
[35] G. Colditz,et al. A prospective study of benign breast disease and the risk of breast cancer , 1992, JAMA.
[36] W. Dupont,et al. Atypical hyperplastic lesions of the female breast: A long-term follow-up study , 1986 .
[37] W D Dupont,et al. Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.
[38] P. Mullins,et al. Progesterone and estrogen receptors as prognostic variables in breast cancer. , 1983, Cancer research.
[39] Johannes Gerdes,et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.